A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 6, 2008, Pages 1069-1073

  Amato, Robert J ^a   Khan, Muhammad ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Capecitabine; Gemcitabine; Interferon ; Metastatic renal cell cancer; Thalidomide

Indexed keywords

ALPHA2A INTERFERON; CAPECITABINE; GEMCITABINE; THALIDOMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE ESCALATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; THALIDOMIDE;

EID: 41049109411     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0568-7     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Thomas A, Murray T, Xu J, Thun M (2007) Cancer statistics. CA Cancer J Clin 57:43-66
2. Motzer RJ, Rini BI, Michaelson MD et al (2004) SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial [abstract]. Proc Am Soc Clin Oncol 23:A4500
3. Motzer RJ, Rini BI, Michaelson MD (2005) Phase II trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol 23:A4508
4. Motzer R, Michaelson MD, Redman B et al (2006) Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24
5. Bukowski RM (2001) Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19:148-154
6. Amato R, Rawat A (2006) Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study. Invest New Drugs 24:171-175
7. Xeloda® (Capecitabine) tablets [package insert] 2003 Nutley, Roche Laboratories
8. Hernberg M, Pyrhonen S, Muhonen T (2006) Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 22:145-146
9. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE (1993) Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597-1599
10. Fujimoto K, Ichimori Y, Yamaguchi H, Arai K, Futami T, Ozono S, Hirao Y, Kakizoe T, Terada M, Okajima E (1995) Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 86:182-186
11. Amato R (2000) Thalidomide for recurrent renal cell cancer in a 40 year old man. Oncology 14:33-36
12. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-765
13. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma renal cell, ovarian and breast cancer. Br J Cancer 82:812-817
14. Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L (2002) A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 20:389-393
15. Stebbing J Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME (2001) The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953-958
16. Amato RJ, Schell J, Thompson N, Moore R, Miles B (2003) Phase II study of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 22:387
17. Rabinoiwtz M, Elias L, Lee F-C (2003) Phase I/II trial of 5-fluorouricil, interferon-α, interleukin-2, and thalidomide for metastatic renal cell cancer. Proc Am Soc Clin Oncol 22:445
18. Sella A, Sternberg C, Yarom N, Sava T, Calabry F, Zisman A, Linder A, Cetto GL (2003) Phase II study of low dose thalidomide and interferon-alpha in metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 22:402
19. Padrik P, Leppik K, Arak A (2003) A phase II study of combination therapy with capecitabine and interferon-alfa2A (IFNa) in patients with metastatic renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol 22:1626